Cognitive impairment in primary brain tumors outpatients: A prospective cross-sectional survey

Chiara Zucchella, Michelangelo Bartolo, Cherubino Di Lorenzo, Veronica Villani, Andrea Pace

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Brain tumors and anti-cancer treatments can cause a wide range of cognitive deficits that in turn, being a major cause of disability, significantly affect patients' independence and quality of life. To evaluate the neurocognitive status of a non selected population of brain tumors outpatients, investigating the correlation with clinical and demographic variables. This prospective cross-sectional survey enrolled consecutive outpatients with a histopathologically confirmed diagnosis of brain tumor. All the patients were evaluated with a battery of standardized neuropsychological tests assessing language, memory, logical-executive functions, attention, visuo-constructional abilities. An univariate regression analysis was performed to assess the impact of socio-demographical and clinical variables on the presence of cognitive impairment. 147 patients (61F/86M, mean age 52.8 ± 13.3, mean schooling 12.7 ± 4 were enrolled into the study. Out of the 147 patients evaluated, 80 (54.4 %) showed cognitive impairment: 43 (53.75 %) presented a multidomain impairment, while 37 (46.25 %) patients revealed cognitive deficits limited respectively to language (n:13, 16.25 %), memory (n:11, 13.75 %), attention (n:7, 8.75 %), logical-executive functions (n:5, 6.25 %), visuo-spatial abilities (n:1, 1.25 %). At the regression analysis the variables significantly related to the development of cognitive impairment were age (p = 0.04), lesion side (p = 0.00), chemotherapy (p = 0.03). As advances in anti-cancer treatment have prolonged life expectancy of neuro-oncological patients, standard clinical endpoints can't be limited to just survival or progression free survival, but have to consider clinical benefits on both motor and cognitive function and in general quality of life. Hence evaluation of new therapeutic strategies should routinely include longitudinal neuropsychological assessment.

Original languageEnglish
Pages (from-to)455-460
Number of pages6
JournalJournal of Neuro-Oncology
Volume112
Issue number3
DOIs
Publication statusPublished - May 2013

Fingerprint

Brain Neoplasms
Outpatients
Cross-Sectional Studies
Executive Function
Language
Regression Analysis
Quality of Life
Aptitude
Neuropsychological Tests
Life Expectancy
Cognition
Disease-Free Survival
Cognitive Dysfunction
Neoplasms
Therapeutics
Demography
Drug Therapy
Survival
Population

Keywords

  • Brain tumor
  • Cognitive deficits
  • Neuro-oncology
  • Neuropsychology

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Cognitive impairment in primary brain tumors outpatients : A prospective cross-sectional survey. / Zucchella, Chiara; Bartolo, Michelangelo; Di Lorenzo, Cherubino; Villani, Veronica; Pace, Andrea.

In: Journal of Neuro-Oncology, Vol. 112, No. 3, 05.2013, p. 455-460.

Research output: Contribution to journalArticle

@article{474be0b20aa3446c8f2d1ce403e3fabc,
title = "Cognitive impairment in primary brain tumors outpatients: A prospective cross-sectional survey",
abstract = "Brain tumors and anti-cancer treatments can cause a wide range of cognitive deficits that in turn, being a major cause of disability, significantly affect patients' independence and quality of life. To evaluate the neurocognitive status of a non selected population of brain tumors outpatients, investigating the correlation with clinical and demographic variables. This prospective cross-sectional survey enrolled consecutive outpatients with a histopathologically confirmed diagnosis of brain tumor. All the patients were evaluated with a battery of standardized neuropsychological tests assessing language, memory, logical-executive functions, attention, visuo-constructional abilities. An univariate regression analysis was performed to assess the impact of socio-demographical and clinical variables on the presence of cognitive impairment. 147 patients (61F/86M, mean age 52.8 ± 13.3, mean schooling 12.7 ± 4 were enrolled into the study. Out of the 147 patients evaluated, 80 (54.4 {\%}) showed cognitive impairment: 43 (53.75 {\%}) presented a multidomain impairment, while 37 (46.25 {\%}) patients revealed cognitive deficits limited respectively to language (n:13, 16.25 {\%}), memory (n:11, 13.75 {\%}), attention (n:7, 8.75 {\%}), logical-executive functions (n:5, 6.25 {\%}), visuo-spatial abilities (n:1, 1.25 {\%}). At the regression analysis the variables significantly related to the development of cognitive impairment were age (p = 0.04), lesion side (p = 0.00), chemotherapy (p = 0.03). As advances in anti-cancer treatment have prolonged life expectancy of neuro-oncological patients, standard clinical endpoints can't be limited to just survival or progression free survival, but have to consider clinical benefits on both motor and cognitive function and in general quality of life. Hence evaluation of new therapeutic strategies should routinely include longitudinal neuropsychological assessment.",
keywords = "Brain tumor, Cognitive deficits, Neuro-oncology, Neuropsychology",
author = "Chiara Zucchella and Michelangelo Bartolo and {Di Lorenzo}, Cherubino and Veronica Villani and Andrea Pace",
year = "2013",
month = "5",
doi = "10.1007/s11060-013-1076-8",
language = "English",
volume = "112",
pages = "455--460",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - Cognitive impairment in primary brain tumors outpatients

T2 - A prospective cross-sectional survey

AU - Zucchella, Chiara

AU - Bartolo, Michelangelo

AU - Di Lorenzo, Cherubino

AU - Villani, Veronica

AU - Pace, Andrea

PY - 2013/5

Y1 - 2013/5

N2 - Brain tumors and anti-cancer treatments can cause a wide range of cognitive deficits that in turn, being a major cause of disability, significantly affect patients' independence and quality of life. To evaluate the neurocognitive status of a non selected population of brain tumors outpatients, investigating the correlation with clinical and demographic variables. This prospective cross-sectional survey enrolled consecutive outpatients with a histopathologically confirmed diagnosis of brain tumor. All the patients were evaluated with a battery of standardized neuropsychological tests assessing language, memory, logical-executive functions, attention, visuo-constructional abilities. An univariate regression analysis was performed to assess the impact of socio-demographical and clinical variables on the presence of cognitive impairment. 147 patients (61F/86M, mean age 52.8 ± 13.3, mean schooling 12.7 ± 4 were enrolled into the study. Out of the 147 patients evaluated, 80 (54.4 %) showed cognitive impairment: 43 (53.75 %) presented a multidomain impairment, while 37 (46.25 %) patients revealed cognitive deficits limited respectively to language (n:13, 16.25 %), memory (n:11, 13.75 %), attention (n:7, 8.75 %), logical-executive functions (n:5, 6.25 %), visuo-spatial abilities (n:1, 1.25 %). At the regression analysis the variables significantly related to the development of cognitive impairment were age (p = 0.04), lesion side (p = 0.00), chemotherapy (p = 0.03). As advances in anti-cancer treatment have prolonged life expectancy of neuro-oncological patients, standard clinical endpoints can't be limited to just survival or progression free survival, but have to consider clinical benefits on both motor and cognitive function and in general quality of life. Hence evaluation of new therapeutic strategies should routinely include longitudinal neuropsychological assessment.

AB - Brain tumors and anti-cancer treatments can cause a wide range of cognitive deficits that in turn, being a major cause of disability, significantly affect patients' independence and quality of life. To evaluate the neurocognitive status of a non selected population of brain tumors outpatients, investigating the correlation with clinical and demographic variables. This prospective cross-sectional survey enrolled consecutive outpatients with a histopathologically confirmed diagnosis of brain tumor. All the patients were evaluated with a battery of standardized neuropsychological tests assessing language, memory, logical-executive functions, attention, visuo-constructional abilities. An univariate regression analysis was performed to assess the impact of socio-demographical and clinical variables on the presence of cognitive impairment. 147 patients (61F/86M, mean age 52.8 ± 13.3, mean schooling 12.7 ± 4 were enrolled into the study. Out of the 147 patients evaluated, 80 (54.4 %) showed cognitive impairment: 43 (53.75 %) presented a multidomain impairment, while 37 (46.25 %) patients revealed cognitive deficits limited respectively to language (n:13, 16.25 %), memory (n:11, 13.75 %), attention (n:7, 8.75 %), logical-executive functions (n:5, 6.25 %), visuo-spatial abilities (n:1, 1.25 %). At the regression analysis the variables significantly related to the development of cognitive impairment were age (p = 0.04), lesion side (p = 0.00), chemotherapy (p = 0.03). As advances in anti-cancer treatment have prolonged life expectancy of neuro-oncological patients, standard clinical endpoints can't be limited to just survival or progression free survival, but have to consider clinical benefits on both motor and cognitive function and in general quality of life. Hence evaluation of new therapeutic strategies should routinely include longitudinal neuropsychological assessment.

KW - Brain tumor

KW - Cognitive deficits

KW - Neuro-oncology

KW - Neuropsychology

UR - http://www.scopus.com/inward/record.url?scp=84885048424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885048424&partnerID=8YFLogxK

U2 - 10.1007/s11060-013-1076-8

DO - 10.1007/s11060-013-1076-8

M3 - Article

C2 - 23417320

AN - SCOPUS:84885048424

VL - 112

SP - 455

EP - 460

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -